ArticleAJO international2026
Maribavir for cytomegalovirus retinitis: A case series and review of the literature.
Article in AJO international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: Therapy for vision-threatening CMV retinitis is often limited by drug resistance or systemic toxicity. Maribavir, a novel UL97 kinase inhibitor that has been FDA-approved for refractory CMV viremia, is a potential alternative to traditional antiviral therapy but remains understudied for CMV retinitis. The objective of this series is to describe the clinical courses and outcomes of patients with CMV retinitis after initiation of maribavir therapy. Design: Retrospective case series. Subjects: Six patients (11 eyes) with CMV retinitis from two tertiary uveitis centers. All were immunocompromised due to chemotherapy, immunotherapy, or AIDS and were initially treated with standard therapy (systemic and/or intravitreal ganciclovir, valganciclovir, or foscarnet) before developing drug resistance, toxicity, or intolerance prompting a transition to maribavir as alternative therapy. Intervention: Oral maribavir 400 mg twice daily. Main Outcome Measures: Time to retinitis quiescence, visual acuity (VA), and adverse effects of therapy. Results: 4/11 eyes had active retinitis upon initiation of maribavir and all achieved quiescence within 6 weeks. The remaining 7/11 eyes were already quiescent and remained so. VA remained stable or improved in all eyes. Notable clinical courses included (1) rapid decline in aqueous CMV titer and resolution of retinitis in a patient with multidrug-resistant CMV failing intravitreal ganciclovir/foscarnet; (2) a patient with UL54-resistant CMV and bilateral macula-involving retinitis rapidly achieving inactivity and preserved visual acuity on maribavir; and (3) successful substitution of maribavir in patients who were unable to continue conventional antiviral therapy due to drug-induced neutropenia or nephrotoxicity. Maribavir was generally well-tolerated, and only mild adverse effects were reported (dysgeusia, myalgia). Review of the literature identified 2 additional cases of patients with similar clinical courses achieving resolution of retinitis on maribavir. Conclusions: In this descriptive case series, patients with multidrug-resistant CMV retinitis or intolerance to traditional antiviral therapy were observed to achieve or maintain quiescence of retinitis following initiation of maribavir. These findings suggest maribavir as a potential novel systemic option for challenging cases of CMV retinitis. Prospective studies are necessary to further characterize the efficacy and safety of maribavir for the treatment of CMV retinitis, as well as optimal duration of therapy after quiescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.